Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 7/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506977 | 0.97 | TAAR1 (0.52) | TAAR1TSHRALDH1A1KCNN4KIF11 | |
| SCHEMBL19566546 | 0.84 | KIF11 (0.58) | TAAR1TSHRALDH1A1KIF11PTPN1 | |
| SCHEMBL6986532 | 0.80 | MAPT (0.44) | TAAR1KCNN4KIF11CA1CA2 | |
| SCHEMBL10159499 | 0.78 | KIF11 (0.50) | TAAR1TSHRALDH1A1KCNN4KIF11 | |
| Hydrochloric Acid SCHEMBL3917461 | 0.78 | TAAR1 (0.53) | TAAR1TSHRKIF11 | |
| SCHEMBL10749002 | 0.77 | TAAR1 (0.52) | TAAR1TSHRALDH1A1KCNN4KIF11 | |
| SCHEMBL3676582 | 0.77 | TAAR1 (0.52) | TAAR1TSHRALDH1A1KCNN4KIF11 | |
| Hydrochloric Acid SCHEMBL29098622 | 0.76 | TSHR (0.42) | TAAR1TSHRKIF11 | |
| Hydrochloric Acid SCHEMBL5408810 | 0.76 | TAAR1 (0.46) | TAAR1TSHRALDH1A1KCNN4KIF11 | |
| Hydrochloric Acid SCHEMBL223449 | 0.76 | KIF11 (0.47) | TAAR1KCNN4KIF11PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011323-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240391917-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-11-28 | — | — | US | disclosed |
| US-12110288-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240124408-A1 | Substituted Cyclohexanecarboxamides, Their Preparation and Their Therapeutic Application | SANOFI (FR) | 2024-04-18 | — | — | US | disclosed |
| EP-4263493-A1 | SUBSTITUTED CYCLOHEXANECARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi (FR) | 2023-10-25 | — | — | EP | disclosed |
| CN-116829532-A | Substituted cyclohexane carboxamides, their preparation and their therapeutic use | 赛诺菲 | 2023-09-29 | — | — | CN | disclosed |
| CN-116332873-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4126848-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2022-10-20 | — | — | US | disclosed |
| EP-4069238-A1 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-114025844-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| WO-2021202781-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| WO-2021113686-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020264176-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI INTERNATIONAL (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-3676266-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | Ctxt Pty Ltd (AU) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| US-20130253022-A1 | NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012074784-A2 | NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE | ADVANCED NEURAL DYNAMICS, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110288-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CA2 2534/4885TAAR1 4685/4885TSHR 3550/4885 |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | KAT5, KAT6A, KAT2A | CA2 4004/4885TAAR1 1982/4885TSHR 3508/4885 |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CA2 2534/4885TAAR1 4685/4885TSHR 3550/4885 |
| US-20240124408-A1 | Substituted Cyclohexanecarboxamides, Their Preparation and Their Therapeutic Application | TRPM8, TAS2R8, TRPM7 | CA2 414/4885TAAR1 130/4885TSHR 190/4885 |
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR119 | CA2 4531/4885TAAR1 28/4885TSHR 499/4885 |
| US-20250011323-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CA2 2534/4885TAAR1 4685/4885TSHR 3550/4885 |
| US-20130253022-A1 | NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE | GRIN2A, GRIK2, GRIK5 | CA2 462/4885TAAR1 3476/4885TSHR 1690/4885 |
| US-20240391917-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CA2 2534/4885TAAR1 4685/4885TSHR 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.